close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ:BIOR)

0.5597 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Provides Outlook for 2024
Multiple catalysts anticipated in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
Patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Submits Updated IND Application for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Submit Updated IND Application for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Autonomous next-gen device exceeded performance targets in three recent preclinical studies 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
Confirmation of autonomous device function enables progress to testing of pharma collaborators’ molecules 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
Intellectual property relates to key features of the company’s liquid jet injection technology 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today